New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2731-7196
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
New treatment options for metastatic HER2-low breast cancer ; day:6 ; month:12 ; year:2022 ; pages:1-8
Die Pathologie ; (6.12.2022), 1-8
- Urheber
-
Denkert, Carsten
Lebeau, Annette
Schildhaus, Hans Ulrich
Jackisch, Christian
Rüschoff, Josef
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00292-022-01139-4
- URN
-
urn:nbn:de:101:1-2023021621125355675294
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Denkert, Carsten
- Lebeau, Annette
- Schildhaus, Hans Ulrich
- Jackisch, Christian
- Rüschoff, Josef
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
Targeted therapies for ER+/HER2- metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Histopathological features predict metastatic potential in locally advanced colon carcinomas
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Histopathological Criteria for Paediatric Adrenocortical Carcinoma
Treatment Options in Metastatic Renal Cell Carcinoma
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
Targeted therapies for ER+/HER2- metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Histopathological features predict metastatic potential in locally advanced colon carcinomas
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Histopathological Criteria for Paediatric Adrenocortical Carcinoma
Treatment Options in Metastatic Renal Cell Carcinoma
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
Targeted therapies for ER+/HER2- metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Histopathological features predict metastatic potential in locally advanced colon carcinomas
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Histopathological Criteria for Paediatric Adrenocortical Carcinoma
Treatment Options in Metastatic Renal Cell Carcinoma
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy